Across TCGA pan-cancer cohorts, NELFA mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated NELFA data layer compared with 19 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NELFA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated NELFA expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where NELFA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.892	0.300	.001	38	view →
COAD	DFS	Median	All	1.000	0.888	.023	18	view →
LUAD	OS	Tertile	II,III,IV	1.000	0.801	.030	12	view →
PDAC	OS	Median	All	0.391	0.579	.018	9	view →
HNSC	OS	Median	All	0.484	1.000	.038	7	view →
LSCC	DFS	Median	All	0.989	0.883	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: NELFA tumor-vs-normal RNA expression · all NELFA data types